Aprea Therapeutics Profit Margin

The latest profit margin for APRE is -368812.14% as of June 2026. That compares with -4275.67% in the prior-year period — down 8525.8% year over year. That is below the Healthcare sector average of 13.71%. Investors often review this figure alongside Aprea Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, APRE's profit margin moved from -4275.67% to -368812.14% — a 8525.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Aprea Therapeutics's valuation or profitability profile.

Against Healthcare companies, APRE currently prints -368812.14% for profit margin, while the sector average sits near 13.71%. That is roughly 2690030.2% below the sector mean. Large gaps often invite a closer look at Aprea Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Aprea Therapeutics converts resources into returns. At -368812.14%, APRE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -4275.67% in the prior-year period — down 8525.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting APRE's profit margin (-368812.14%), review year-over-year change from -4275.67%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.